SureScripts launches national record locator service

Surescripts, the nation’s largest health information network, will implement its National Record Locator Service with EHR vendors eClinicalWorks, Epic, and Greenway Health, enabling more than 480,000 providers to use the new service to locate and exchange patient health records. 

Surescripts’ National Record Locator Service will be implemented according to the Carequality framework for inter-network health information exchange, consisting of legal agreements that enforce the responsibilities in Carequality’s Principles of Trust, and implementation guides that outline business and technical requirements.

The national electronic prescription company’s new service is a federate query and response solution that integrated into the provider workflow through existing EHR software. 

"Leveraging Surescripts' National Record Locator Service, we can offer our customers an enormous lean in search and record location capabilities," said Carl Dvorak, president of Epic, in the release. "We look forward to partnering with other payers, vendors and provider organizations to make it easier to find and aggregate patient medical records, regardless of where they have received care, all while ensuring the highest level of security, privacy and patient consent."

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.